Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10132382 | 0.99 | GPR119 (0.46) | GPR119ALDH1A1LMNAMAPTRORC | |
| SCHEMBL2713151 | 0.91 | GPR119 (0.49) | GPR119ALDH1A1LMNAMAPTRORC | |
| SCHEMBL9951786 | 0.91 | GPR119 (0.49) | GPR119ALDH1A1LMNAMAPTRORC | |
| SCHEMBL2727269 | 0.91 | GPR119 (0.55) | GPR119ALDH1A1LMNAMAPTRORC | |
| SCHEMBL2712292 | 0.90 | GPR119 (0.45) | GPR119ALDH1A1LMNAMAPTRORC | |
| SCHEMBL2727935 | 0.87 | GPR119 (0.47) | GPR119ALDH1A1LMNAMAPTRORC | |
| SCHEMBL2728940 | 0.84 | GPR119 (0.42) | GPR119ALDH1A1LMNAMAPTRORC | |
| SCHEMBL10132386 | 0.84 | MAPT (0.47) | ALDH1A1LMNAMAPTPDK2MGLL | |
| SCHEMBL2727537 | 0.84 | ALDH1A1 (0.41) | ALDH1A1MAPTRORCMGLL | |
| SCHEMBL23752795 | 0.83 | MGLL (0.54) | RORCMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906913-B2 | Azabicyclohexanes | PANACEA BIOTEC LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| EP-2445887-B1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD (IN) | 2014-11-05 | — | — | EP | disclosed |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
| EP-2445887-A2 | NOVEL AZABICYCLOHEXANES | Panacea Biotec Limited (IN) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010150281-A2 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | GPR119 1235/4885ALDH1A1 295/4885LMNA 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.